### Tables

1.1 Estimated 2004 US sales losses due to copyright piracy in 52 selected countries  
6.1 A timeline for India’s patent law  
6.2 Number of companies in the Indian pharmaceutical industry  
6.3 Characteristics of the Indian pharmaceutical industry  
6.4 India’s ten largest pharmaceutical companies by market capitalization in 2004  
6.5 India’s ten largest pharmaceutical companies by sales in 2004  
6.6 Strengths and opportunities for the Indian pharmaceutical industry  
6.7 India’s top-ten pharmaceutical companies’ R&D expenditures  
6.8 India’s domestic patent growth  
6.9 Indian post-reform pharmaceutical patents  
6.10 Pre- and post-reform patents for Indian pharmaceutical companies  
6.11 Percentage of process-oriented patents in India’s pharmaceutical companies  
13.1 Evolution of average IPR index scores for developing countries, 1990–2000  
13.3 The relationship between merchandise import flows and patent protection, 1990–2005  
13.4 Estimates of relationship between inward FDI stock and patent protection, 1990–2005  
13.5 Estimates of relationship between outward US FDI stock in developing countries and patent protection, by industry, 1990–2005  
13.6 Royalty and licensing fees for the use of intangible assets, received from abroad by US parent firms  
13.7 Intellectual property rights: royalty and licensing fees from unaffiliated sources, firm level  
13.8 Intellectual property rights and US royalty and licensing fees relative to trade and foreign direct investment  
13.9 The relationship between patent reform and high-tech licensing transactions in developing countries